AZNCF News and Press, AstraZeneca Plc From 07/28/20

Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...

2020 has been a crazy year. We have experienced an unprecedented money flow into growth/tech stocks , disfavoring value stocks (stocks which are trading below their fundamentals based on their earnings and/or dividends). In fact, the Nasdaq ( QQQ ) is up ~18% year-to-date compared to a decl...

Investment Thesis The much-awaited peer-reviewed data of mRNA-1273, the COVID-19 vaccine candidate of Moderna, Inc. ( MRNA ), has left many questions unanswered. Though the vaccine has been safe and produced neutralizing antibodies, the Phase 3 trial will look for the vaccine's clinical ef...

Quick Take AlloVir ( ALVR ) intends to raise $251 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is a mid stage firm developing drug treatments for virus conditions. ALVR is preparing to enter Phase 3 trials and has an e...

Quick Take iTeos Therapeutics ( ITOS ) intends to raise $151 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a range of treatments for various cancers, including solid tumors. ITOS is pursuing treatments for...

Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

Quick Take AlloVir ( ALVR ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is a mid-stage clinical biopharma firm developing treatments for various virus infections. ALVR is seeking funding to advance its lead cand...

Many investors dumped BELLUS Health ( BLU ) because the company's Phase 2 trial did not offer good results. They appear to forget that BELLUS Health is planning to execute Phase 2b results. If the results are a bit better, the share price will most likely creep up. Besides, the company is targ...

Quick Take ALX Oncology ( ALXO ) intends to raise $128 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatment candidates for various blood and solid tumor cancer conditions. ALXO is pursuing treatments in...

Mortality defines the human condition. - Drew Gilpin Faust Investor interest in the biotech industry will likely endure for a long time If you're part of my Lead-Lag report-reading cohort, you'll know that I've been providing regular updates on the developments and the performance of o...